MX369782B - Formulaciones solidas que contienen omega-3 y resveratrol. - Google Patents
Formulaciones solidas que contienen omega-3 y resveratrol.Info
- Publication number
- MX369782B MX369782B MX2016013189A MX2016013189A MX369782B MX 369782 B MX369782 B MX 369782B MX 2016013189 A MX2016013189 A MX 2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A MX 369782 B MX369782 B MX 369782B
- Authority
- MX
- Mexico
- Prior art keywords
- omega
- resveratrol
- formulations containing
- solid formulations
- containing omega
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14001940.7A EP2952180B1 (en) | 2014-06-04 | 2014-06-04 | Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA) |
| PCT/EP2015/056530 WO2015185239A1 (en) | 2014-06-04 | 2015-03-26 | Solid formulations containing omega-3 and resveratrol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013189A MX2016013189A (es) | 2017-01-16 |
| MX369782B true MX369782B (es) | 2019-11-21 |
Family
ID=50884650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013189A MX369782B (es) | 2014-06-04 | 2015-03-26 | Formulaciones solidas que contienen omega-3 y resveratrol. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170112791A1 (https=) |
| EP (1) | EP2952180B1 (https=) |
| JP (1) | JP2017522278A (https=) |
| CN (1) | CN106456587B (https=) |
| AU (1) | AU2015271278A1 (https=) |
| CA (1) | CA2943021A1 (https=) |
| EA (1) | EA032762B1 (https=) |
| ES (1) | ES2615630T3 (https=) |
| MX (1) | MX369782B (https=) |
| PL (1) | PL2952180T3 (https=) |
| PT (1) | PT2952180T (https=) |
| SI (1) | SI2952180T1 (https=) |
| UA (1) | UA119174C2 (https=) |
| WO (1) | WO2015185239A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050233074A1 (en) * | 2002-08-14 | 2005-10-20 | Dalziel Sean M | Solid flowable powder with high liquid loading |
| ITRM20020562A1 (it) | 2002-11-06 | 2004-05-07 | Sigma Tau Ind Farmaceuti | Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza. |
| WO2009034124A1 (en) * | 2007-09-12 | 2009-03-19 | Novozymes A/S | Omega-3 stabilisation towards oxidation |
| KR101100078B1 (ko) * | 2008-03-27 | 2011-12-29 | 홉킨스바이오연구센터(주) | 관절염 치료를 위한 약제학적 조성물 |
| US9005608B2 (en) * | 2009-03-24 | 2015-04-14 | Adds Pharmaceuticals Llc | Stabilized solubility-enhanced formulations for oral delivery |
| KR20120104270A (ko) | 2009-12-23 | 2012-09-20 | 데피안떼 파마슈띠까 에스.에이. | 심혈관계 질환 치료에 유용한 복합 조성물 |
| US20110244031A1 (en) * | 2010-03-31 | 2011-10-06 | Lifecycle Pharma A/S | Porous tablets as carriers for liquid formulations |
| IT1400695B1 (it) | 2010-06-21 | 2013-06-28 | Labomar S R L | Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle. |
| DK3181119T3 (da) * | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
-
2014
- 2014-06-04 EP EP14001940.7A patent/EP2952180B1/en active Active
- 2014-06-04 SI SI201430151A patent/SI2952180T1/sl unknown
- 2014-06-04 PT PT140019407T patent/PT2952180T/pt unknown
- 2014-06-04 ES ES14001940.7T patent/ES2615630T3/es active Active
- 2014-06-04 PL PL14001940T patent/PL2952180T3/pl unknown
-
2015
- 2015-03-26 JP JP2016570875A patent/JP2017522278A/ja active Pending
- 2015-03-26 EA EA201692399A patent/EA032762B1/ru not_active IP Right Cessation
- 2015-03-26 WO PCT/EP2015/056530 patent/WO2015185239A1/en not_active Ceased
- 2015-03-26 CA CA2943021A patent/CA2943021A1/en not_active Abandoned
- 2015-03-26 CN CN201580029892.0A patent/CN106456587B/zh not_active Expired - Fee Related
- 2015-03-26 US US15/316,152 patent/US20170112791A1/en not_active Abandoned
- 2015-03-26 AU AU2015271278A patent/AU2015271278A1/en not_active Abandoned
- 2015-03-26 UA UAA201613089A patent/UA119174C2/uk unknown
- 2015-03-26 MX MX2016013189A patent/MX369782B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PT2952180T (pt) | 2017-03-02 |
| EP2952180B1 (en) | 2017-01-25 |
| MX2016013189A (es) | 2017-01-16 |
| US20170112791A1 (en) | 2017-04-27 |
| JP2017522278A (ja) | 2017-08-10 |
| CN106456587B (zh) | 2020-03-20 |
| PL2952180T3 (pl) | 2017-05-31 |
| SI2952180T1 (sl) | 2017-05-31 |
| AU2015271278A1 (en) | 2016-11-10 |
| EP2952180A1 (en) | 2015-12-09 |
| UA119174C2 (uk) | 2019-05-10 |
| ES2615630T3 (es) | 2017-06-07 |
| CA2943021A1 (en) | 2015-12-10 |
| CN106456587A (zh) | 2017-02-22 |
| EA032762B1 (ru) | 2019-07-31 |
| EA201692399A1 (ru) | 2017-03-31 |
| WO2015185239A1 (en) | 2015-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170253A1 (es) | Lipido que comprende acidos grasos poliinsaturados de cadena larga | |
| Betancor et al. | Influence of dietary docosahexaenoic acid in combination with other long-chain polyunsaturated fatty acids on expression of biosynthesis genes and phospholipid fatty acid compositions in tissues of post-smolt Atlantic salmon (Salmo salar) | |
| MX349678B (es) | Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales. | |
| MX2018003636A (es) | Composicion de uridina y citidina para su uso en la prevencion o tratamiento de neurotrauma. | |
| MX372724B (es) | Formulaciones de acido eicosapentaenoico (epa). | |
| MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| PH12014500105A1 (en) | Fatty acid compositions | |
| MX356427B (es) | Emulsion que contiene hormona. | |
| GEP201606568B (en) | Compositions for the treatment of neurologic disorders | |
| WO2016040570A3 (en) | Dietary emulsion formulations and methods for using the same | |
| BR112014013593A8 (pt) | retenção de dha durante o processamento de óleo de canola | |
| UA111967C2 (uk) | Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання | |
| MX386098B (es) | Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas. | |
| BR112017013445A2 (pt) | processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 6 poli-insaturados | |
| CO2017001088A2 (es) | Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas | |
| WO2014165190A3 (en) | Compositions comprising docosapentaenoic acid and methods of use | |
| MX2015007085A (es) | Composiciones de acido omega-3 pentanoico y metodos de uso. | |
| PL3784044T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| PL3809858T3 (pl) | Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha | |
| PH12017500738A1 (en) | Feeding algae to cattle at low doses to produce high omega 3 levels in beef | |
| CO2017005911A2 (es) | Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas | |
| MX369782B (es) | Formulaciones solidas que contienen omega-3 y resveratrol. | |
| MX2022005627A (es) | Lipido que comprende acido docosapentaenoico. | |
| MX2016013190A (es) | Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral. | |
| BR112018070194A2 (pt) | composto e composição para uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ALFASIGMA S.P.A. |
|
| FG | Grant or registration |